Multi-target therapeutics: when the whole is greater than the sum of the parts.

By G. Zimmermann, Joseph Lehar, Curtis T. Keith. Drug Discovery Today, 2007

1,034 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Molecular Biology, Organic Chemistry

View Paper: https://www.semanticscholar.org/paper/b7195fc127046d799d3ae444afc10ab2a440875c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

In Molecular Biology

Citations in the corpus

Network target for screening synergistic drug combinations with application to traditional Chinese medicine (2011, background): “This finding is not surprising, because synergistic effects in multicomponent therapeutics could be achieved by genes that are involved in different biological processes related to a disease [1].”
Synergistic drug combinations improve therapeutic selectivity (2009, positive): “One empirical method for finding potential multitarget therapies is to seek synergistic responses to combined perturbing agents, like drugs, using phenotypes that arise from the concerted function of several cellular function”
Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review (2012, background): “• Via the above, ‘indirect’ targeting, and via their low affinity binding, multi-target drugs may avoid the presently common dual-trap of drug-resistance and toxicity (Lipton, 2004; Csermely et al., 2005; Lehár et al., 2007; Zimmermann et al., 2007; Ohlson, 2008; Savino et al., 2012).”
Natural products and drug discovery (2009, background): “This new strategy could have several advantages as it would modulate biological networks rather modestly and might therefore be more efficient in dealing with complex diseases (Csermely et al, 2005; Dancey & Chen 2006; Zimmermann et al, 2007).”
Systematic prediction of drug combinations based on clinical side-effects (2014, methodology): “We discussed the differences between our methods and previous work 13 in more details in the supplemental materials (Supplementary Result 2).”
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery (2011, background): “efficacies, improved safety profiles and reduced resistance activities (12,38,42).”
Analysis of drug combinations: current methodological landscape (2015, background): “The enhanced understanding of the biology of a disease as a disturbed system of interconnected molecular pathways which are more susceptible to the simultaneous action of several drugs, provides new opportunities for the rational development of combination therapies (Smalley et al. 2006; Kitano 2007”
Discovery and resupply of pharmacologically active plant-derived natural products: A review (2015, background): “weakly active compounds which act additively or synergistically (Junio et al., 2011; Kurin et al., 2012; Wagner and Ulrich-Merzenich, 2009; Zimmermann et al., 2007).”
Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics (2017, background): “Moreover, the multi-target drugs (25,26) and drug combinations (25,27,28) directed at specific target combinations have been extensively tested and used for enhanced therapeutics.”
Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis (2009, background): “If it is proven in future studies that entacapone can inhibit multiple targets simultaneously, the potential of entacapone as an anti-tubercular drug is even more promising, as ‘‘dirty’’ drugs lessen the likelihood of emergent resistance and higher clinical efficacy than exquisitely selective drugs ”